Index S&P 500
P/E 79.51
EPS (ttm) 2.40
Insider Own 0.08%
Shs Outstand 1.77B
Perf Week 3.64%
Market Cap 336.82B
Forward P/E 13.69
EPS next Y 13.92
Insider Trans -0.13%
Shs Float 1.77B
Perf Month 6.17%
Income 4.25B
PEG 5.21
EPS next Q 2.52
Inst Own 73.05%
Short Float 1.03%
Perf Quarter -5.49%
Sales 56.33B
P/S 5.98
EPS this Y 21.27%
Inst Trans -0.24%
Short Ratio 2.71
Perf Half Y 1.65%
Book/sh 3.41
P/B 55.84
EPS next Y 13.44%
ROA 3.63%
Short Interest 18.16M
Perf Year 9.99%
Cash/sh 4.12
P/C 46.23
EPS next 5Y 15.26%
ROE 56.06%
52W Range 153.58 - 207.32
Perf YTD 7.26%
Dividend Est. 6.45 (3.39%)
P/FCF 21.61
EPS past 5Y -14.51%
ROI 6.58%
52W High -8.06%
Beta 0.62
Dividend TTM 6.29 (3.30%)
Quick Ratio 0.54
Sales past 5Y 12.19%
Gross Margin 84.51%
52W Low 24.10%
ATR (14) 4.51
Dividend Ex-Date Jan 15, 2025
Current Ratio 0.65
EPS Y/Y TTM -21.61%
Oper. Margin 29.61%
RSI (14) 66.36
Volatility 2.62% 2.21%
Employees 50000
Debt/Eq 11.78
Sales Y/Y TTM 3.71%
Profit Margin 7.54%
Recom 1.77
Target Price 207.40
Option/Short Yes / Yes
LT Debt/Eq 9.70
EPS Q/Q -102.71%
Payout 260.68%
Rel Volume 0.57
Prev Close 192.97
Sales Surprise 1.82%
EPS Surprise 2.12%
Sales Q/Q 5.60%
Earnings Jan 31 BMO
Avg Volume 6.70M
Price 190.60
SMA20 6.82%
SMA50 7.15%
SMA200 6.15%
Trades
Volume 3,787,120
Change -1.23%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-10-24 Resumed
BofA Securities
Neutral
$191
Dec-05-24 Downgrade
Daiwa Securities
Outperform → Neutral
$180
Nov-22-24 Upgrade
Leerink Partners
Market Perform → Outperform
$206
Nov-15-24 Initiated
Wolfe Research
Outperform
$205
Nov-04-24 Upgrade
Argus
Hold → Buy
Oct-17-24 Initiated
Bernstein
Mkt Perform
$203
Jun-05-24 Upgrade
HSBC Securities
Hold → Buy
$185
May-17-24 Initiated
Cantor Fitzgerald
Overweight
$200
Jan-29-24 Upgrade
William Blair
Mkt Perform → Outperform
Dec-18-23 Downgrade
HSBC Securities
Buy → Hold
Dec-11-23 Upgrade
Goldman
Neutral → Buy
Nov-09-23 Initiated
Deutsche Bank
Hold
$150
Oct-30-23 Upgrade
Barclays
Equal Weight → Overweight
$160 → $170
Oct-20-23 Resumed
UBS
Neutral
$157 → $150
Sep-29-23 Initiated
Raymond James
Outperform
$177
Jul-25-23 Initiated
William Blair
Mkt Perform
Jul-14-23 Initiated
HSBC Securities
Buy
$167
Apr-05-23 Downgrade
Argus
Buy → Hold
Mar-01-23 Initiated
Guggenheim
Buy
$172
Feb-22-23 Downgrade
Wolfe Research
Outperform → Peer Perform
Show Previous Ratings
Today 08:30AM
Feb-07-25 01:27PM
Feb-06-25 09:45AM
09:00AM
08:05AM
07:48AM
Loading…
07:48AM
(Pharmaceutical Technology)
05:07AM
Feb-05-25 03:51PM
09:00AM
07:00AM
(The Wall Street Journal)
Feb-04-25 11:33AM
06:01AM
Feb-03-25 04:42PM
Feb-02-25 04:10PM
Feb-01-25 06:05AM
02:05AM
Loading…
02:05AM
01:26AM
(Thomson Reuters StreetEvents)
Jan-31-25 04:11PM
(Investor's Business Daily)
04:01PM
(Investor's Business Daily)
03:59PM
01:45PM
12:42PM
12:16PM
12:02PM
10:50AM
10:50AM
10:36AM
10:21AM
10:00AM
09:30AM
08:51AM
Loading…
08:51AM
(Investor's Business Daily)
08:45AM
08:26AM
07:44AM
(Associated Press Finance)
07:40AM
07:36AM
Jan-30-25 07:00PM
01:30PM
10:00AM
Jan-29-25 09:00AM
04:00AM
Jan-28-25 06:15AM
06:01AM
Jan-27-25 06:21PM
09:17AM
Jan-25-25 11:06AM
Jan-24-25 05:45PM
10:00AM
06:17AM
05:48AM
04:01AM
(Pharmaceutical Technology)
04:00AM
Jan-23-25 12:42PM
09:16AM
09:00AM
Jan-22-25 02:58PM
01:44PM
12:03PM
Jan-21-25 06:22PM
04:04PM
(Investor's Business Daily)
07:10AM
06:01AM
04:17AM
Jan-20-25 07:50AM
Jan-19-25 12:01PM
Jan-18-25 05:01PM
11:21AM
08:20AM
Jan-17-25 12:15PM
09:46AM
Jan-16-25 05:45PM
11:41AM
03:56AM
Jan-15-25 07:30PM
04:04PM
10:47AM
(Pharmaceutical Technology)
Jan-14-25 01:38PM
09:25AM
09:00AM
08:15AM
06:01AM
05:15AM
Jan-13-25 03:13PM
(The Wall Street Journal)
09:05AM
09:00AM
09:00AM
09:00AM
08:31AM
Jan-11-25 03:38AM
Jan-10-25 12:04PM
11:10AM
09:16AM
(The Wall Street Journal)
06:43AM
Jan-09-25 08:00AM
Jan-07-25 05:45PM
12:10PM
08:00AM
06:01AM
04:41AM
Jan-06-25 04:45PM
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Buckbee Kevin K SVP, CONTROLLER Dec 16 '24 Option Exercise 93.50 1,800 168,300 8,783 Dec 18 05:00 PM Buckbee Kevin K SVP, CONTROLLER Dec 16 '24 Sale 172.24 1,800 310,032 6,983 Dec 18 05:00 PM Buckbee Kevin K Officer Dec 16 '24 Proposed Sale 172.25 1,800 310,045 Dec 16 05:34 PM Hudson Thomas J Officer Aug 08 '24 Proposed Sale 189.08 49,170 9,297,210 Aug 08 05:40 PM GONZALEZ RICHARD A EXECUTIVE CHAIRMAN OF BOARD Aug 05 '24 Sale 186.52 66,500 12,403,580 446,599 Aug 07 05:00 PM Hudson Thomas J Officer Aug 07 '24 Proposed Sale 187.62 101,886 19,115,380 Aug 07 04:22 PM GONZALEZ RICHARD A Officer Aug 05 '24 Proposed Sale 187.36 66,500 12,459,360 Aug 05 10:54 AM GONZALEZ RICHARD A EXECUTIVE CHAIRMAN OF BOARD Jul 17 '24 Option Exercise 77.49 282,845 21,919,048 795,944 Jul 19 04:40 PM GONZALEZ RICHARD A EXECUTIVE CHAIRMAN OF BOARD Jul 17 '24 Sale 175.00 282,845 49,497,875 513,099 Jul 19 04:40 PM Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER Mar 20 '24 Sale 176.30 21,082 3,716,757 55,903 Mar 22 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 18 '24 Option Exercise 61.36 26,110 1,602,110 119,890 Mar 20 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 18 '24 Sale 178.79 58,949 10,539,508 60,941 Mar 20 05:00 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Mar 01 '24 Option Exercise 61.36 45,700 2,804,152 89,517 Mar 05 05:30 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Mar 01 '24 Sale 177.27 75,680 13,415,503 13,837 Mar 05 05:30 PM Reents Scott T EVP, CHIEF FINANCIAL OFFICER Feb 23 '24 Option Exercise 61.36 14,140 867,630 41,205 Mar 01 05:50 PM Reents Scott T EVP, CHIEF FINANCIAL OFFICER Feb 23 '24 Sale 177.44 14,140 2,509,002 27,065 Mar 01 05:50 PM Buckbee Kevin K SVP, CONTROLLER Feb 29 '24 Sale 176.65 5,144 908,688 6,983 Mar 01 05:50 PM Michael Robert A. PRES & CHIEF OPERATING OFFICER Feb 29 '24 Option Exercise 58.30 21,560 1,257,012 167,524 Mar 01 05:50 PM Michael Robert A. PRES & CHIEF OPERATING OFFICER Feb 29 '24 Sale 176.45 68,879 12,153,957 98,645 Mar 01 05:50 PM Siatis Perry C EVP, GC AND SECRETARY Feb 29 '24 Sale 177.39 9,891 1,754,555 10,397 Mar 01 05:50 PM GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO Feb 28 '24 Sale 177.27 138,616 24,572,458 519,099 Mar 01 05:50 PM Siatis Perry C EVP, GC AND SECRETARY Feb 23 '24 Option Exercise 137.36 13,753 1,889,115 41,926 Feb 27 05:10 PM Siatis Perry C EVP, GC AND SECRETARY Feb 23 '24 Sale 177.51 13,753 2,441,295 28,173 Feb 27 05:10 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Feb 21 '24 Option Exercise 58.88 52,870 3,112,986 296,814 Feb 23 05:00 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Feb 21 '24 Sale 173.71 52,870 9,184,048 243,944 Feb 23 05:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite